Suven Life Science gains on acquiring Suven Pharmaceuticals
Suven Life Sciences is currently trading at Rs. 206.10, up by 0.55 points or 0.27% from its previous closing of Rs. 205.55 on the BSE.
The scrip opened at Rs. 202.40 and has touched a high and low of Rs. 211.45 and Rs. 202.40 respectively. So far 28877 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 337.70 on 11-Sep-2018 and a 52 week low of Rs. 163.30 on 23-Mar-2018.
Last one week high and low of the scrip stood at Rs. 211.45 and Rs. 188.40 respectively. The current market cap of the company is Rs. 2616.29 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 8.48% and 31.52% respectively.
Suven Life Science has acquired all the shares of Suven Pharmaceuticals (SPL), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals has become a wholly owned subsidiary of the company. The board of directors at their meetings held on February 5, 2019, approved the same. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
A Special Offer for a Special Season! Get Stock Cash Tips to start from 2 Days Free Trial Click Here- Stock Cash Tips "we provide secure, Smooth Deals You Can Trust"
0 comments
Note: only a member of this blog may post a comment.